Skip to main content
A Case in Contrasts: How Should the Media Talk About Cancer Diagnoses?
Rahul Banerjee, MD, FACP
From the Editor's Desk
Only a week ago, transatlantic media coverage of the British monarchy quickly pivoted from discussions about photo editing to discussions about adjuvant chemotherapy when Catherine, Princess of Wales revealed that she had been diagnosed with cancer (Kwai, 2024). Since then, many media outlets have raced to interview oncologists about her ...
A 2024 Kickoff Message From Dr. Rahul Banerjee, Editor in Chief
Rahul Banerjee, MD, FACP
From the Editor's Desk
Many of us are ushering in the New Year singing "Auld Lang Syne" (or some version of those lyrics) with an eye toward ensuring that old acquaintances never be forgotten. Conversely, as we ring in 2024, it's worth noting how many of our old-acquaintance oncology drugs have actually remained at our side. Pembrolizumab was first approved in September ...
A Letter to Oncology Data Advisor Readers From Rahul Banerjee, MD, FACP, and Thomas Abrams, MD
Rahul Banerjee, MD, FACP
Expert Analysis
Oncology Data Advisor is excited to announce that Rahul Banerjee, MD, FACP, has been appointed the new Editor in Chief. Dr. Banerjee, an Assistant Professor of Medicine in the Division of Oncology at the University of Washington, Fred Hutchinson Cancer Center, has taken over the role from Thomas Abrams, MD, Assistant Professor of Medicine at H...
A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD, Editor in Chief
Thomas Abrams, MD
From the Editor's Desk
Hot enough for ya? While large swaths of the United States bake in an unrelenting summer heat wave, Oncology Data Advisor is having quite a summer hot streak of our own. We are honored to have received an APEX Award of Excellence for Health and Medical Websites. This is an extraordinary achievement that reflects the creativity and dedication of the...
A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD: Spring 2023
Thomas Abrams, MD
From the Editor's Desk
I am honored to continue my tenure as Editor in Chief of Oncology Data Advisor in 2023. The last year was a thrill for me, as the post afforded me a front-row seat to lectures, panel discussions, and podcasts from some of the most respected names in our field. I can assure you that what we have planned for 2023 is even more ambitious with multiple interview series, long-form essays, and oncology-focused podcasts available nowhere else.
A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD
Thomas Abrams, MD
From the Editor's Desk
I am thrilled to announce that I will be staying on as Editor in Chief of Oncology Data Advisor for at least another year. It gives me such great joy to work with such an accomplished group of experts in oncology, as well as with an extremely professional core of editors headed up by Keira Smith. We have grand plans for 2023. In the meantime, pleas...
A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD
Thomas Abrams, MD
From the Editor's Desk
It's been a busy three months here at Oncology Data Advisor (ODA) since I last banged out an "Editor's Notes." One of the highlights was ODA's presence at the American Society of Clinical Oncology (ASCO) Annual Meeting. Many researchers spoke on camera with us about the work they were presenting at the meeting, and visibility for the website increa...
A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD: May 2022
Thomas Abrams, MD
From the Editor's Desk
From my perch atop the masthead at Oncology Data Advisor, I am awed by the dozens of oncology professionals who give freely of their time and expertise to inform our readership of the latest in their respective areas. Their efforts are what make ODA a premier online resource for all things in this ever-evolving field. My heartfelt thanks go to thes...
A Letter to Oncology Data Advisor Readers From Thomas Abrams, MD
Thomas Abrams, MD
From the Editor's Desk
It is my pleasure to assume the post of Editor in Chief of Oncology Data Advisor for 2022. One of the perks of this role is the opportunity to speak directly to you, the readership, about everything we are up to here. Not only do we strive to give you trenchant summaries of the latest and most relevant oncology treatment breakthroughs in print, pod...